Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

In situ single-cell analysis of canonical breast cancer biomarkers: phenotypic heterogeneity and implications on response to HER2 targeting agents

Garazi Serna, Eloy García, Roberta Fasani, Xavier Guardia, Tomas Pascual, Laia Paré, Fiorella Ruiz-Pace, Antonio Llombart-Cussac, Javier Cortes, Aleix Prat, Paolo Nuciforo
doi: https://doi.org/10.1101/2022.09.21.508826
Garazi Serna
1Molecular oncology group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eloy García
2Department of Mathematics and Informatics, University of Barcelona, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roberta Fasani
1Molecular oncology group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xavier Guardia
1Molecular oncology group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tomas Pascual
3Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain
4Department of Medical Oncology, Hospital Clínic de Barcelona, Barcelona, Spain
5SOLTI Breast Cancer Research Group, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laia Paré
6Reveal Genomics, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fiorella Ruiz-Pace
7Oncology Data Science Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonio Llombart-Cussac
8Department of Medical Oncology, Hospital Arnau de Vilanova, Valencia, Spain; FISABIO, Universidad Católica de Valencia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Javier Cortes
9International Breast Cancer Center (IBCC), Quirónsalud Group, Barcelona, Spain; Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain; Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aleix Prat
3Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain
4Department of Medical Oncology, Hospital Clínic de Barcelona, Barcelona, Spain
5SOLTI Breast Cancer Research Group, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paolo Nuciforo
1Molecular oncology group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
5SOLTI Breast Cancer Research Group, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: pnuciforo@vhio.net
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Preview PDF
Loading

ABSTRACT

Breast cancer is a heterogeneous disease. Tumor cells and the surrounding microenvironment form an ecosystem that determine disease progression and response to therapy. To characterize the breast cancer ecosystem and the changes induced by targeted treatment selective pressure, we analyzed 136 HER2-positive tumor samples for the expression of canonical BC tumor diagnostic proteins at a single cell level without disrupting the spatial context. The combined expression of HER2, ER, PR, and Ki67 in more than a million cells was evaluated using a tumor-centric panel combining the four biomarkers in a single tissue section by sequential immunohistochemistry to derive 16 tumor cell phenotypes. Spatial interactions between individual tumor cells and cytotoxic T cells were studied to determine the immune characteristics of the ecosystem and the impact on response to treatment. HER2-positive tumors displayed individuality in tumor cells and immune cells composition, including intrinsic phenotype dominance which only partially overlapped with molecular intrinsic subtyping determined by PAM50 analysis. This single cell analysis of canonical BC biomarkers deepens our understanding of the complex biology of HER2-positive BC and suggests that individual cell-based patient classification may facilitate identification of optimal responders or resistant individual to HER2-targeted therapies.

Competing Interest Statement

Dr. Prat, is equity stockholders of Reveal Genomics; also consultants of Reveal Genomics and reports grants from Reveal Genomics; other from Reveal Genomics, personal fees from Roche, grants and personal fees from AstraZeneca, grants and personal fees from Daiichi-Sankyo, grants and personal fees from Novartis, personal fees from Foundation Medicine, personal fees from Oncolytics Biotech, outside the submitted work; In addition, Dr. Prat has a patent HER2DX licensed to Reveal Genomics, and a patent WO 2018/103834 licensed to Reveal Genomics. Dr. Pare has a patent HER2DX licensed to Reveal Genomics. Dr. Nuciforo reports consulting fees of advisory boards from Bayer, MSD and Novartis and speaker fees from MSD and Novartis. All other authors declared no competing interest.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted September 22, 2022.
Download PDF

Supplementary Material

Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
In situ single-cell analysis of canonical breast cancer biomarkers: phenotypic heterogeneity and implications on response to HER2 targeting agents
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
In situ single-cell analysis of canonical breast cancer biomarkers: phenotypic heterogeneity and implications on response to HER2 targeting agents
Garazi Serna, Eloy García, Roberta Fasani, Xavier Guardia, Tomas Pascual, Laia Paré, Fiorella Ruiz-Pace, Antonio Llombart-Cussac, Javier Cortes, Aleix Prat, Paolo Nuciforo
bioRxiv 2022.09.21.508826; doi: https://doi.org/10.1101/2022.09.21.508826
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
In situ single-cell analysis of canonical breast cancer biomarkers: phenotypic heterogeneity and implications on response to HER2 targeting agents
Garazi Serna, Eloy García, Roberta Fasani, Xavier Guardia, Tomas Pascual, Laia Paré, Fiorella Ruiz-Pace, Antonio Llombart-Cussac, Javier Cortes, Aleix Prat, Paolo Nuciforo
bioRxiv 2022.09.21.508826; doi: https://doi.org/10.1101/2022.09.21.508826

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Pathology
Subject Areas
All Articles
  • Animal Behavior and Cognition (4232)
  • Biochemistry (9128)
  • Bioengineering (6774)
  • Bioinformatics (23989)
  • Biophysics (12117)
  • Cancer Biology (9523)
  • Cell Biology (13772)
  • Clinical Trials (138)
  • Developmental Biology (7627)
  • Ecology (11686)
  • Epidemiology (2066)
  • Evolutionary Biology (15505)
  • Genetics (10638)
  • Genomics (14322)
  • Immunology (9479)
  • Microbiology (22832)
  • Molecular Biology (9089)
  • Neuroscience (48962)
  • Paleontology (355)
  • Pathology (1480)
  • Pharmacology and Toxicology (2568)
  • Physiology (3844)
  • Plant Biology (8327)
  • Scientific Communication and Education (1471)
  • Synthetic Biology (2296)
  • Systems Biology (6187)
  • Zoology (1300)